Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) Non Operating Income (2020 - 2025)

Insight Molecular Diagnostics' Non Operating Income history spans 6 years, with the latest figure at $194000.0 for Q3 2025.

  • For Q3 2025, Non Operating Income rose 781.82% year-over-year to $194000.0; the TTM value through Sep 2025 reached $484000.0, down 12.64%, while the annual FY2024 figure was $378000.0, 4.06% down from the prior year.
  • Non Operating Income for Q3 2025 was $194000.0 at Insight Molecular Diagnostics, up from $71000.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $1.3 million in Q2 2021 and bottomed at -$196000.0 in Q3 2021.
  • The 5-year median for Non Operating Income is $24000.0 (2023), against an average of $98421.1.
  • The largest annual shift saw Non Operating Income crashed 107.65% in 2022 before it soared 15400.0% in 2024.
  • A 5-year view of Non Operating Income shows it stood at -$47000.0 in 2021, then skyrocketed by 480.85% to $179000.0 in 2022, then skyrocketed by 50.28% to $269000.0 in 2023, then tumbled by 76.95% to $62000.0 in 2024, then soared by 212.9% to $194000.0 in 2025.
  • Per Business Quant, the three most recent readings for IMDX's Non Operating Income are $194000.0 (Q3 2025), $71000.0 (Q2 2025), and $157000.0 (Q1 2025).